Skip to main content
HN13 clinical trial opens in Canada investigating precision radiation therapy

HN13 clinical trial opens in Canada investigating precision radiation therapy for head and neck cancer

The HN13 clinical trial has recently opened in Canada and will explore a new radiotherapy technique called stereotactic body radiotherapy (SBRT) to treat patients with advanced head and neck cancer. Researchers want to know if SBRT offers better cancer and symptom control than the standard radiotherapy (RT). “This trial will harness the most advanced technology in radiation oncology to deliver a more precise and effective radiation treatment that we hope will lead to better quality of life and better survival compared to the standard of care,” says study lead Dr. Ian Poon, radiation oncologist, Sunnybrook Odette Cancer Centre. SBRT uses specialized techniques to deliver higher than usual doses of radiation focused on the area where the cancer is present. It is believed that this therapy may be better at controlling tumours without damaging surrounding normal tissue. This new therapy option could benefit frail patients who have difficulty tolerating the more frequent RT treatments that often result in long term side effects.

More >>
 
myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment

myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment

The myeloMATCH North American platform study is now open in Canada and comprises a series of clinical trials to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

More >>
 
Cancer Cooperative Group leaders propose a re-engineering of the nation’s correlative science program for cancer

Cancer Cooperative Group leaders propose a re-engineering of the nation’s correlative science program for cancer

The Journal of Clinical Oncology has published ‘Correlative Science in the Cooperative Group System—Re-Engineering for Success,’ which proposes public-private partnerships to increase resources and process innovations to open access to tissue banks

More >>
 
CCTG NE2 (STOPNET) neuroendocrine study has officially open in Canada.

CCTG NE2 neuroendocrine study has opened in Canada

The CCTG NE2 STOPNET neuroendocrine study has officially open in Canada. Researchers are investigating whether somatostatin analogues (SSA) are needed after targeted therapy for patients with neuroendocrine tumours.

More >>
 

Planned trials

ALC9

Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

BR38

Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

HE2

SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma

MD1

CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)

PAC5

Lanreotide for the Prevention of Postoperative Pancreatic Fistula

PR26

Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)

SC30

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT

SC31

Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)

CE10

VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma

CO33

Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial

SR8

NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)

SKC1

Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma

Recently activated

AL6

MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

More >>

ALC8

Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

More >>

BLC6

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

More >>

BR36

CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer

More >>

CE9

Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)

More >>

ES3

NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)

More >>

HN13

Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer

More >>

MAC30

Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score More >>

NE2

STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Tumours

More >>

PM2

Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated with Immuno-Oncotherapeutics (CAN-IMPACT-IO)

More >>

PR25

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

More >>

SC29

Stereotactic Body Radiotherapy (SBRT) vs Conventional Palliative Radiotherapy (CRT) for Participants with Painful Non-Spine Bone Metastases

More >>

SRC8

Doxorubicin + Pembrolizumab vs Doxorubicin for Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

More >>

VU2

STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

More >>
Welcome to Patient Representative Michelle Audoin

Welcome to Patient Representative Michelle Audoin

Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.

More >>
 
Patient Representative Suzanne Wood

Welcome to Patient Representative Suzanne Wood

CCTG would like to extend a warm welcome to Patient Representative Suzanne Wood who will be supporting the GI disease site committee. Suzanne is from Toronto and was diagnosed with Stage IV Colon cancer in July 2022.

More >>
 
Welcoming new Patient Representative Haydn Bechthold

Welcoming new Patient Representative Haydn Bechthold

CCTG would like to welcome our new Patient Representative Haydn Bechthold who will be supporting the Gastrointestinal Disease Site Committee.

More >>
 
Welcome to Patient Representative Jasmine Heuring

Welcome to Patient Representative Jasmine Heuring

A very warm welcome to Jasmine Heuring who has joined the CCTG Patient Representatives Committee and will be supporting the Adolescents & Young Adults and Sarcoma Disease Site Committees. Jasmine is from Winnipeg Manitoba and is a cancer advocate and healthcare analyst.

More >>